Hanmi Holdings Co. Ltd. has synthesized new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of cancer.
Zhongshan Institute for Drug Discovery has divulged new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of cancer, neurodegeneration, malaria, AIDS, gout, diabetes, renal failure and cardiovascular disorders, among others.
Ewha Womans University and Gachon University have discovered new pyrazinocarbazole derivatives acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of colorectal cancer.
Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Merck Sharp & Dohme LLC and Peloton Therapeutics Inc. have described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Hanmi Pharmaceutical Co Ltd. has synthesized new heterobicyclic compounds acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors and reported to be useful for the treatment of cancer.
The University of Parma and the University of Modena and Reggio Emilia have jointly disclosed new transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.
Dong-A ST Co. Ltd. has disclosed transcriptional enhancer factor (TEAD) and/or transcriptional coactivator YAP1/TEAD interaction inhibitors reported to be useful for the treatment of cancer.
Daewoong Pharmaceutical Co. Ltd. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
